Search Results

You are looking at 1 - 1 of 1 items for

  • Author: TY Tai x
  • Refine by access: Content accessible to me x
Clear All Modify Search
TY Tai
Search for other papers by TY Tai in
Google Scholar
PubMed
Close
,
JY Lu
Search for other papers by JY Lu in
Google Scholar
PubMed
Close
,
CL Chen
Search for other papers by CL Chen in
Google Scholar
PubMed
Close
,
MY Lai
Search for other papers by MY Lai in
Google Scholar
PubMed
Close
,
PJ Chen
Search for other papers by PJ Chen in
Google Scholar
PubMed
Close
,
JH Kao
Search for other papers by JH Kao in
Google Scholar
PubMed
Close
,
CZ Lee
Search for other papers by CZ Lee in
Google Scholar
PubMed
Close
,
HS Lee
Search for other papers by HS Lee in
Google Scholar
PubMed
Close
,
LM Chuang
Search for other papers by LM Chuang in
Google Scholar
PubMed
Close
, and
YM Jeng
Search for other papers by YM Jeng in
Google Scholar
PubMed
Close

This study aimed at elucidating the effects of interferon (IFN)-alpha on glucose metabolism in patients with chronic hepatitis B and C infections. Twenty-eight biopsy-proven patients with chronic hepatitis B (ten cases) and hepatitis C (18 cases) were given IFN-alpha for a total of 24 weeks. The patients received a 75 g oral glucose tolerance test (OGTT), glucagon stimulation test, tests for type 1 diabetes-related autoantibodies and an insulin suppression test before and after IFN-alpha therapy. Ten of the 28 patients responded to IFN-alpha therapy. Steady-state plasma glucose of the insulin suppression test decreased significantly in responders (13.32+/-1.48 (S.E.M.) vs 11.33+/-1.19 mmol/l, P=0.0501) but not in non-responders (12.29+/-1.24 vs 11.11+/-0.99 mmol/l, P=0.2110) immediately after completion of IFN-alpha treatment. In the oral glucose tolerance test, no significant difference was observed in plasma glucose in either responders (10.17+/-0.23 vs 10.03+/-0.22 mmol/l) or non-responders (10.11+/-0.22 vs 9.97+/-0.21 mmol/l) 3 Months after completion of IFN-alpha treatment. However, significant differences were noted in C-peptide in both responders (2.90+/-0.13 vs 2.20+/-0.09 nmol/l, P=0.0040) and non-responders (2.45+/-0.11 vs 2.22+/-0.08 nmol/l, P=0.0287) before vs after treatment. The changes of C-peptide in an OGTT between responders and non-responders were also significantly different (P=0.0028), with responders reporting a greater reduction in C-peptide. No case developed autoantibodies during the treatment. In patients who were successfully treated with IFN-alpha, insulin sensitivity improved and their plasma glucose stayed at the same level without secreting as much insulin from islet beta-cells.

Free access